Baseline® Guide Volume 6: Biopharmaceuticals (Second Edition)

Print this page         
Guide Cover

Publication Date: December 2013

Pages: 140

 

Table of Contents ( 237 KB)

Formats Member Price Nonmember Price  
Bound Version $200 / €155 $495 / €395 buy now
Individual Download $200 / €155 $495 / €395 buy now

This second edition of the ISPE Baseline® Guide: Biopharmaceutical Manufacturing Facilities intends to further reinforce the concepts described in the first edition of the Guide, provide examples of how these concepts can be put into practice, and detail the value and benefits of the approach described.

The biopharmaceutical industry has adapted to reflect available technologies, products with more focused patient populations, regulatory conditions, and continued pressures on costs.  The Guide develops concepts to reflect how these changes affect Biopharmaceutical Facilities without sacrificing product quality, by reducing risk and enhancing the manufacturing control strategy.

The Guide emphasizes the use of closed systems as an approach to mitigating risks associated with the production of biopharmaceuticals.

Concepts presented within the Guide apply to different scales of operation, from individual liters to tens of thousands of liters. The Guide applies to new Clinical and Commercial CGMP production facilities for the development and manufacture of biopharmaceutical Active Pharmaceutical Ingredients (or Drug Substances).

Types of Drug Substances considered in this Guide include:

  • protein therapeutics
  • synthetic proteins
  • polypeptides
  • monoclonal antibodies
  • vaccines
  • biopharmaceutical Drug Substances isolated from tissues or body fluids
  • transgenic biopharmaceutical Drug Substances
  • gene therapy biopharmaceutical Drug Substances
  • stem cells 

The intended audience for this Guide includes industry professionals involved in the design, construction, qualification, and operation of Biopharmaceutical Manufacturing Facilities as well as regulatory and quality personnel involved in evaluating technical decisions associated with Biopharmaceutical Manufacturing Facility design.

This Guide is not intended to be used in the retrofit of older facilities; however, the execution of these concepts and strategies can be evaluated and implemented as it benefits production in a major modification to an existing facility.

Last Update: 10 December 2013

My ISPE

  • Click to go to My Communities of Practice
  • Click to go to My Affiliate or Chapter
  • Click to go to My Profile
Click to go to the Member Gift